+ New Watchlist

Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Neurocrine Biosciences

NBIXNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$135.42

0.460.34%

At close: -

$135.42

0.000.00%

After Hours: Dec 20, 4:03 PM EDT

Neurocrine Biosciences (NBIX) Forecast

News

Earnings Neurocrine Biosciences (NBIX) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences Stock (NASDAQ: NBIX)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, December 20, 2024

What Analysts Are Saying About Neurocrine Biosciences Stock
Benzinga Insights
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk

Monday, December 16, 2024

Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Vandana Singh
Wedbush Reiterates Outperform on Neurocrine B...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Neurocr...
Benzinga Newsdesk
Reported Friday, Neurocrine Biosciences' CREN...
Benzinga Newsdesk

Tuesday, December 03, 2024

Screening For Black Friday Bargains In The Stock Market
David Pinsen

Wednesday, November 13, 2024

Strategic Sale: EIRY ROBERTS Decides To Exercise Options Worth $334K At Neurocrine Biosciences
Benzinga Insights

Tuesday, November 12, 2024

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
Vandana Singh

Monday, November 11, 2024

Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk

Thursday, November 07, 2024

Neurocrine Biosciences Unveils KINECT-HD Data...
Benzinga Newsdesk

Monday, November 04, 2024

Neurocrine Biosciences Reveals New INGREZZA D...
Benzinga Newsdesk

Friday, November 01, 2024

HC Wainwright & Co. Reiterates Buy on Neurocr...
Benzinga Newsdesk

Thursday, October 31, 2024

Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk

Wednesday, October 30, 2024

Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Neurocrine Biosciences Raises FY24 Net Produc...
Benzinga Newsdesk
Neurocrine Biosciences Board Authorizes $300M...
Benzinga Newsdesk
Neurocrine Biosciences Q3 2024 Adj. EPS $1.81...
Benzinga Newsdesk

Tuesday, October 29, 2024

In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences
Benzinga Insights
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk

Thursday, October 17, 2024

BMO Capital Maintains Market Perform on Neuro...
Benzinga Newsdesk

Thursday, October 10, 2024

Raymond James Reinstates Outperform on Neuroc...
Benzinga Newsdesk

Tuesday, October 08, 2024

RBC Capital Reiterates Sector Perform on Neur...
Benzinga Newsdesk

Friday, October 04, 2024

Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know
Benzinga Insights
RBC Capital Maintains Sector Perform on Neuro...
Benzinga Newsdesk

Monday, September 30, 2024

Neurocrine Biosciences Highlights Presentatio...
Benzinga Newsdesk

Monday, September 16, 2024

Cantor Fitzgerald Reiterates Overweight on Ne...
Benzinga Newsdesk

Friday, September 13, 2024

Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
Vandana Singh

Thursday, September 12, 2024

Neurocrine Biosciences Provides Update on ERU...
Benzinga Newsdesk

Monday, September 09, 2024

Decoding 19 Analyst Evaluations For Neurocrine Biosciences
Benzinga Insights
Barclays Maintains Overweight on Neurocrine B...
Benzinga Newsdesk

Sunday, September 08, 2024

Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
Lekha Gupta

Monday, September 02, 2024

Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
Lekha Gupta

Thursday, August 29, 2024

Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
Vandana Singh
Cantor Fitzgerald Maintains Overweight on Neu...
Benzinga Newsdesk
RBC Capital Maintains Sector Perform on Neuro...
Benzinga Newsdesk
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
HC Wainwright & Co. Reiterates Buy on Neurocr...
Benzinga Newsdesk
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Piper Sandler Upgrades Neurocrine Biosciences...
Benzinga Newsdesk
BMO Capital Maintains Market Perform on Neuro...
Benzinga Newsdesk

Wednesday, August 28, 2024

Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
Avi Kapoor
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Vandana Singh
US Stocks Mixed; JM Smucker Slashes Annual Guidance
Avi Kapoor
Neurocrine Biosciences shares are trading low...
Benzinga Newsdesk
Neurocrine Biosciences Announced Positive Top...
Benzinga Newsdesk

Tuesday, August 27, 2024

Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Anthony Noto

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved